- Home
- REBN vs RNAZ Comparison
REBN vs RNAZ Comparison
Compare REBN & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REBN | RNAZ |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 8.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REBN | RNAZ |
|---|---|---|
| Price | $1.48 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $280.00 |
| AVG Volume (30 Days) | ★ 46.1K | 18.6K |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,663,303.00 | N/A |
| Revenue This Year | $335.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.09 | N/A |
| 52 Week Low | $1.20 | $6.08 |
| 52 Week High | $8.30 | $468.44 |
Technical Indicators
Market Signals| Indicator | REBN | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 32.96 |
| Support Level | $1.38 | $6.08 |
| Resistance Level | $1.55 | $7.67 |
| Average True Range (ATR) | 0.12 | 0.88 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 29.94 | 11.30 |
Price Performance
Historical ComparisonAbout REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.